logo
Twitter
Discord
Email
logo
Outset Medical, Inc.

Outset Medical, Inc.

NASDAQ•OM
CEO: Ms. Leslie L. Trigg
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2020-09-15
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Contact Information
3052 Orchard Drive, San Jose, CA, 95134, United States
669-231-8200
www.outsetmedical.com
Market Cap
$96.21M
P/E (TTM)
-1.1
32.4
Dividend Yield
--
52W High
$21.98
52W Low
$3.10
52W Range
12%
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$29.43M+2.67%
4-Quarter Trend

EPS

-$1.00+81.82%
4-Quarter Trend

FCF

-$6.48M-69.09%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Total revenue reached $90.6M for nine months ended September 30, 2025, showing an 8% increase versus 2024.
Gross Profit Improvement Gross profit grew 24% to $34.5M for nine months, driven by cost reduction in service and product revenue.
Net Loss Significantly Reduced Net loss narrowed to $(62.2M)$ for nine months, a substantial improvement from the $(102.3M)$ loss reported previously.
Operating Expenses Down Total operating expenses decreased 30% to $83.6M for nine months, reflecting successful cost structure optimization efforts.

Risk Factors

Pending Stockholder Litigation Company faces consolidated stockholder class action lawsuits alleging misleading statements; litigation is currently in early stages.
Macroeconomic Spending Caution Rising interest rates and policy uncertainty may cause customers to defer Tablo purchases, elongating sales cycles.
Supply Chain and Tariff Risks Reliance on Mexico manufacturing exposes operations to potential adverse impacts from increased tariffs or trade restrictions.
Cybersecurity Vulnerabilities Reliance on cloud technology and remote work increases exposure to security breaches, potentially harming reputation and operations.

Outlook

Acute Care Market Penetration Focus remains on broadening installed base by targeting national IDNs, SNFs, and LTACHs for Tablo adoption.
Home Dialysis Expansion Significant growth opportunity exists in home hemodialysis; investing in market development and optimizing home distribution logistics.
Path to Profitability Strategy Achieving profitability depends on expanding gross margins through cost reduction and successfully optimizing overall spending.
Sufficient Liquidity Confirmed Existing cash, short-term investments, and recent financing provide sufficient resources to meet anticipated needs for next 12 months.

Peer Comparison

Revenue (TTM)

Inogen, Inc.INGN
$347.03M
+4.7%
Viemed Healthcare, Inc.VMD
$254.79M
+18.1%
Quanterix CorporationQTRX
$130.10M
-2.5%

Gross Margin (Latest Quarter)

CVRx, Inc.CVRX
86.8%
+3.6pp
Electromed, Inc.ELMD
78.1%
-0.2pp
Caribou Biosciences, Inc.CRBU
71.3%
-28.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
QTRX$345.66M-3.6-30.5%9.0%
VMD$284.30M20.810.1%12.2%
ELMD$232.12M28.318.7%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.0%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 18, 2026
|
EPS:-$0.45
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $29.43M+2.7%
    |
    EPS: $-1.00+81.8%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $31.42M+14.7%
    |
    EPS: $-1.04+57.6%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $29.75M+5.6%
    |
    EPS: $-7.44+853.8%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|
    Revenue: $113.69M-12.8%
    |
    EPS: $-2.46+29.3%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $28.67M-5.6%
    |
    EPS: $-0.55-40.9%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $27.39M-24.0%
    |
    EPS: $-0.66-26.7%
    Meet

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $28.17M-15.8%
    |
    EPS: $-0.78-13.3%
    Meet

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $130.38M+13.0%
    |
    EPS: $-3.48-3.0%
    Beat